Cetrotide is a drug owned by Emd Serono Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 23, 2019. Details of Cetrotide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6319192 | Method for the treatment of fertility disorders |
Apr, 2019
(5 years ago) |
Expired
|
| US6863891 | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(10 years ago) |
Expired
|
| US7605121 | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cetrotide's patents.
Latest Legal Activities on Cetrotide's Patents
Given below is the list of recent legal activities going on the following patents of Cetrotide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 Nov, 2017 | US7605121 |
| Sequence Moved to Public Database | 10 Nov, 2009 | US7605121 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Oct, 2009 | US7605121 |
| Recordation of Patent Grant Mailed Critical | 20 Oct, 2009 | US7605121 |
| Issue Notification Mailed Critical | 30 Sep, 2009 | US7605121 |
| Dispatch to FDC | 16 Sep, 2009 | US7605121 |
| Application Is Considered Ready for Issue Critical | 14 Sep, 2009 | US7605121 |
| Issue Fee Payment Verified Critical | 10 Sep, 2009 | US7605121 |
| Issue Fee Payment Received Critical | 10 Sep, 2009 | US7605121 |
| Sequence Forwarded to Pubs on Tape | 06 Jul, 2009 | US7605121 |
US patents provide insights into the exclusivity only within the United States, but Cetrotide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cetrotide's family patents as well as insights into ongoing legal events on those patents.
Cetrotide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cetrotide's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 23, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cetrotide Generic API suppliers:
Cetrorelix Acetate is the generic name for the brand Cetrotide. 4 different companies have already filed for the generic of Cetrotide, with Gland having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cetrotide's generic
About Cetrotide
Cetrotide is a drug owned by Emd Serono Inc. It is used for preventing premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide uses Cetrorelix Acetate as an active ingredient. Cetrotide was launched by Emd Serono Inc in 2000.
Approval Date:
Cetrotide was approved by FDA for market use on 11 August, 2000.
Active Ingredient:
Cetrotide uses Cetrorelix Acetate as the active ingredient. Check out other Drugs and Companies using Cetrorelix Acetate ingredient
Treatment:
Cetrotide is used for preventing premature LH surges in women undergoing controlled ovarian stimulation.
Dosage:
Cetrotide is available in powder form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 3MG BASE/VIAL | POWDER | Discontinued | SUBCUTANEOUS |
| EQ 0.25MG BASE/VIAL | POWDER | Prescription | SUBCUTANEOUS |